PARAGLIDE-HF Offers Further Insight into Sacubitril/Valsarta

Presented at ESC HFA 2023, results of PARAGLIDE-HF detail the effects of sacubitril/valsartan on NT-proBNP and multiple clinical outcomes, relative to valsartan alone, in patients with HFmrEF or HFpEF.

Related Keywords

Carlj Lavie , Hectoro Ventura , Mandeepr Mehra , Sacubitril Valsartan , European Society Of Cardiology , Duke University Medical Center Robert Mentz , Heart Failure Association , Journal Of The American College Cardiology , Duke University Medical Center , Robert Mentz , European Society , Failure Association , American College ,